Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina

Markers of inflammation as predictors in cardiovascular disease

Recent research suggests that inflammation in the coronary arteries may be intimately involved in the development of atherosclerosis and its associated acute coronary syndromes. Experimental and clinical studies based on the biochemical markers of inflammation and vascular perturbation in plasma as well as in atherosclerotic tissue have provided substantial evidence of ongoing inflammation in coronary heart disease. These studies have suggested a potential role for biochemical markers of inflammation in the prediction of risk for the development of coronary heart disease as well as in the prediction of adverse cardiac-related outcomes in patients with known coronary syndromes. Markers of inflammation appear to offer risk prediction information that is independent of, and possibly complementary to, traditional risk factors for the development of cardiovascular disease. There are numerous potential markers for these inflammatory processes and their interdependence remains somewhat unclear. Clinical studies have investigated some, but not all of these markers in a critical and comparative fashion. Therefore, further well-designed prospective studies should elucidate the role of markers of inflammation in the prediction, diagnosis, and management of cardiovascular disease.

Predictive value of C-reactive protein in patients with unstable angina pectoris undergoing coronary artery stent implantation

This study was aimed at establishing the relation between baseline C-reactive protein levels and 12-month outcome in patients with unstable angina successfully treated with coronary artery stent implantation. Our results suggest that in patients with unstable angina and 1-vessel coronary disease successfully treated with coronary artery stent implantation, normal baseline serum levels of C-reactive protein identify a subgroup of patients at low risk of cardiac events during follow-up.

Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty

OBJECTIVES

We sought to investigate whether early and late outcome after percutaneous transluminal coronary angioplasty (PTCA) could be predicted by baseline levels of acute-phase reactants.

BACKGROUND

Although some risk factors for acute complications and restenosis have been identified, an accurate preprocedural risk stratification of patients undergoing PTCA is still lacking.

METHODS

Levels of C-reactive protein (CRP), serum amyloid A protein (SAA) and fibrinogen were measured in 52 stable angina and 69 unstable angina patients undergoing single vessel PTCA.

RESULTS

Tertiles of CRP levels (relative risk [RR] = 12.2, p < 0.001), systemic hypertension (RR = 4.3, p = 0.046) and female gender (RR = 4.1, p = 0.033) were the only independent predictors of early adverse events. Intraprocedural and in-hospital complications were observed in 22% of 69 patients with high serum levels (>0.3 mg/dl) of CRP and in none of 52 patients with normal CRP levels (p < 0.001). Tertiles of CRP levels (RR = 6.2, p = 0.001), SAA levels (RR = 6.0, p = 0.011), residual stenosis (RR = 3.2, p = 0.007) and acute gain (RR = 0.3, p = 0.01) were the only independent predictors of clinical restenosis. At one-year follow-up, clinical restenosis developed in 63% of patients with high CRP levels and in 27% of those with normal CRP levels (p < 0.001).

CONCLUSIONS

Preprocedural CRP level, an easily measurable marker of acute phase response, is a powerful predictor of both early and late outcome in patients undergoing single vessel PTCA, suggesting that early complications and clinical restenosis are markedly influenced by the preprocedural degree of inflammatory cell activation.